“When Heptares formed, we chose to focus on GPCRs because we knew that targeting these receptors leads to drugs,” says Matt Barnes, president and head of R&D at Nxera Pharma. GPCRs are ...

Lilly has bought into Lycia's lysosomal targeting chimera (LYTAC) protein degradation technology, developed by Bertozzi at Stanford University, with an initial focus on projects in immunological ...

Year to date, shares of VKTX and GPCR have plunged 38.9% and 30.1%, respectively, compared with the industry’s 6.4% decline. Image Source: Zacks Investment Research VKTX is currently evaluating ...